Feedback Share Discussion Threads

[ged5] 29/11/2021 15:40

OK Ptolemy, thanks for giving your reasons.

I'd have liked to know how excess applications were to be scaled down. I suppose we'll just find out when our accounts are updated.

[ptolemy] 29/11/2021 15:15

Ged,
His bio and the background of hVivo as an offshoot of a university responsible for conducting studies isn't the skill set I'd look for to commercialise Bleepa+. That's all I'm saying. Only time will tell whether he cuts it as a director/CFO.

[ged5] 29/11/2021 15:05

Thanks for your reply.

I saw he was from hVivo. I thought perhaps you might have known something more like Friel got rid of him.

So you're not sure about him being a director. You OK with him being CFO?

[ptolemy] 29/11/2021 14:56

Ged,

He comes from hVivo. hVivo's primary role is to conduct studies. As far I can see from a quick look they've never commercialised anything. Happy to be proved wrong.

[ged5] 29/11/2021 14:39

"Using part of the proceeds of the Fundraising, the Company is planning to undertake a pilot scheme of the tuberculosis screening solution within some initial sites in India. The Director's believe that there is potential to generate significant revenues per year from each state that the solution is rolled out in."

[desflurane] 29/11/2021 14:39

Market unimpressed

[ged5] 29/11/2021 14:34

Reason please?

"The Company is also pleased to announce that, in relation to the Open Offer, which closed for receipt of applications at 11.00 a.m. on 26 November 2021 in accordance with its terms, received valid applications, including excess applications, from Qualifying Shareholders for more than twice the number of Open Offer Shares available. Consequently, the number of Open Offer Shares subscribed for has been subject to scale-back and 71,428,571 Open Offer Shares, being the maximum number of Open Offer Shares available pursuant to the terms of the Open Offer, are expected to be issued."

[ptolemy] 29/11/2021 14:26

New appointment - the word 'lightweight' comes to mind.

[ged5] 29/11/2021 14:23

Wait for one and two come along.

[lr2] 28/11/2021 21:52

Subsudiary of EQS Group, a leading European Cloud provider.

[petekand] 28/11/2021 21:34

No LR2. This is a complete different company as far as I can tell.

[lr2] 28/11/2021 21:21

Sweden next?

[petekand] 28/11/2021 20:43

Has the emperor any clothes?

The South African doctor who treated early cases of the Omicron variant told the BBC countries could be "panicking unnecessarily" and the symptoms she had seen were "extremely mild".
Dr Angelique Coetzee, chair of the South African Medical Association, said she had first encountered the variant in patients who had fatigue, aches and pains, but no cough or change in sense of smell or taste. "We haven't admitted anyone," she said.

[ged5] 28/11/2021 11:47

I thought more questions than answers.

Is centralisation a good thing? I suppose it is if FDBK is chosen.

Also the website is littered with references to the NHSX framework. So what is going to happen to that list of suppliers?

And why have the website people chosen Dorian Gray as a patient on the first page?

[ducatiman] 28/11/2021 11:12

“Centralisation”. Excellent!

[ragnarr] 28/11/2021 09:45

WHO Global TB Report 2021 - knowing it is one of FDBKs main target market some may wish to have a read.https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2021

[ragnarr] 28/11/2021 09:29

What does the merger of NHS Digital and NHSX with NHS England mean?https://www.digitalhealth.net/2021/11/what-does-the-merger-of-nhs-digital-and-nhsx-with-nhs-england-mean/

[chopper harris1] 27/11/2021 21:10

Thanks Pete.

[petekand] 27/11/2021 20:49

Yes the four cases of the new variant found in Botswana were all fully jabbed up people. How strange.
Did the BBC mention this?

[petekand] 27/11/2021 20:40

Cheap and cheerful never let me down although they also do one which has your picture.



Regarding the eye problem, you may not be alone as the government own figures show over 20,000 reports of adverse reactions concerning the eyes and including total blindness following on from the jab.